Psychedelics for Mental Health Treatment: A Review

Abstract

Psychedelics have re-emerged as a promising area of research in the field of mental health treatment, offering novel therapeutic approaches for a range of psychiatric conditions. This review examines the role of psychedelic substances, including psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and ketamine, in the management of disorders such as depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders. It explores their mechanisms of action, particularly their interaction with serotonergic systems, enhancement of neural plasticity, and capacity to facilitate profound psychological experiences. The review also highlights the importance of structured therapeutic frameworks, including preparation, guided administration, and post-session integration, in maximizing treatment outcomes. Evidence from recent clinical trials suggests that psychedelic-assisted therapies may produce rapid and sustained improvements, particularly in treatment-resistant cases. However, concerns related to safety, ethical considerations, and regulatory limitations remain significant.

Furthermore, this paper discusses the historical context of psychedelic use, the factors contributing to renewed scientific interest, and the influence of “set and setting” on therapeutic effectiveness. While findings are encouraging, the review emphasizes the need for large-scale, long-term studies to establish standardized protocols and ensure safe clinical implementation.

Overall, psychedelics represent a potentially transformative approach in mental health care, with the capacity to complement or, in some cases, redefine existing treatment paradigms.